A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This study will investigate the efficacy and safety of CellCept (1.5-2g/day po), in
combination with a standard care regimen of cyclosporine A (trough level 150-200ng/mL) and
steroids, in patients receiving a heart transplant. The anticipated time on study treatment
is 24 weeks.